Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory [Yahoo! Finance]
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Yahoo! Finance
We came across a bullish thesis on Zenas BioPharma, Inc. on Danny's Substack by Danny Green. In this article, we will summarize the bulls' thesis on ZBIO. Zenas BioPharma, Inc.'s share was trading at $27.02 as of February 19th. ZBIO's trailing P/E was 1.93 according to Yahoo Finance. Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800 Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. ZBIO is transitioning from a pre-revenue stage to commercialization, with analysts projecting revenues to rise from near zero to $30 million in 2026 and significant growth thereafter. Its lead asset, obexelimab, targets IgG4-Related Disease (IgG4-RD), a market with no approved therapies, offering a rare at-home treatment option that avoids B-cell depletion and reduces infection risk. This unique mechanism via CD19/Fc?RIIb preserves patients' immune systems and represents
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)PR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIOPR Newswire
- Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.MarketBeat
ZBIO
Earnings
- 11/12/25 - Miss
ZBIO
Sec Filings
- 2/13/26 - Form 4
- 2/13/26 - Form 4
- 2/13/26 - Form 8-K
- ZBIO's page on the SEC website